SCHEMBL987963

SCHEMBL987963

CCCC(=O)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.64
ACE P12821 6/20 0.62
PSMB5 P28074 1/20 0.61
ITGB3 P05106 1/20 0.60
ITGA2B P08514 1/20 0.60
NAALAD2 Q9Y3Q0 1/20 0.57
CHRNB2 P17787 1/20 0.57
CHRNB4 P30926 1/20 0.57
CHRNA3 P32297 1/20 0.57
CHRNA4 P43681 1/20 0.57
MME P08473 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CPA1 P15085 1/20 0.56
ACE2 Q9BYF1 1/20 0.56
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265066 1.00 FAAH (0.64) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL11793269 1.00 FAAH (0.64) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL15692406 0.94 PSMB5 (0.66) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL7893850 0.92 MME (0.63) FAAHACEITGB3ITGA2BMME
SCHEMBL2565532 0.91 FAAH (0.73) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL15155391 0.91 FAAH (0.73) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL9716668 0.91 FAAH (0.73) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL9666252 0.89 FAAH (0.79) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL8467930 0.89 FAAH (0.79) FAAHACEPSMB5ITGB3ITGA2B
SCHEMBL16449189 0.89 PSMB5 (0.60) FAAHACEPSMB5CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220221433-A1 MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES METABOLON, INC. 2022-07-14 US claimed
EP-3977112-A1 MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES Metabolon Inc. (US) 2022-04-06 EP claimed
CN-113892029-A Mass spectrometry method for detecting metabolites 梅塔博隆股份有限公司 2022-01-04 CN claimed
WO-2020242744-A1 MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES METABOLON, INC. (US) 2020-12-03 WO claimed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US claimed
US-4859653-A Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin MORELLE JEAN V (FR) 1989-08-22 US claimed
EP-3805237-B1 SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) 2026-01-28 EP disclosed
US-20250295713-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2025-09-25 US disclosed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 EP disclosed
US-12064459-B2 Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes DERMBIONT, INC. (US) 2024-08-20 US disclosed
CN-118488855-A Solid composition comprising peptide or protein and acylated amino acid 阿道恰公司 2024-08-13 CN disclosed
EP-4387638-A1 GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM BiomEdit, LLC (US) 2024-06-26 EP disclosed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US disclosed
EP-2268605-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY Berni Canani, Roberto (IT) 2011-01-05 EP disclosed
WO-2009130735-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY BERNI CANANI ROBERTO (IT) 2009-10-29 WO disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed
US-4151198-A Resolution of N-acyl-DL (+)-phenylalanines AMERICAN CYANAMID COMPANY (US) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY FABP2, FFAR2, VIP FAAH 102/4885ACE 1078/4885PSMB5 1845/4885
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP FAAH 858/4885ACE 684/4885PSMB5 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.